update from checkmate 057: nivolumab versus docetaxel in advanced non-squamous nsclc
Published 8 years ago • 202 plays • Length 4:04Download video MP4
Download video MP3
Similar videos
-
1:45
updates from checkmate 017 and checkmate 057: nivolumab, anti-pd1, for non-small cell lung cancer
-
1:36
quality of life and symptom control for non-squamous nsclc patients on nivolumab (checkmate 057)
-
8:48
checkmate 057 trial of nivolumab (nivo) versus docetaxel (doc) in non-sq-nsclc
-
0:57
nivolumab/ docetaxel shows promise for nsclc in checkmate 057 trial
-
2:22
dr. borghaei on 2-year findings with nivolumab vs docetaxel in nsclc
-
1:14
nivolumab compared to docetaxel in patients with nsclc
-
8:23
nivolumab extends survival for nsclc
-
1:49
adverse events of nivolumab in patients with advanced, non-squamous nsclc
-
1:54
dr. brahmer on impact of checkmate-057 in nsclc
-
1:24
checkmate 77t: perioperative nivolumab in nsclc - onctalk lung 2023
-
0:47
checkmate 171: phase 2 trial of nivolumab for advanced squamous cell non-small cell lung cancer
-
2:29
dr. spigel on checkmate 017- phase iii trial for nivolumab - sarah cannon
-
10:45
immunotherapy for non-squamous nsclc: should we be using biomarker selection?
-
3:44
immunotherapy as combination and neoadjuvant therapies in nsclc
-
17:08
three-year update from the checkmate 227 clinical trial for advanced nsclc
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
2:19
checkmate 274: biomarkers linked to disease-free survival with adjuvant nivolumab
-
3:13
attraction-3: nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma